Unión Europea - sueco - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - talidomid - multipelt myelom - immunsuppressiva - thalidomide bms in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged >/= 65 years or ineligible for high dose chemotherapy. thalidomide bms is prescribed and dispensed according to the thalidomide celgene pregnancy prevention programme (see section 4.

Unión Europea - sueco - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - dexametason - macular edema; uveitis - ophthalmologicals, other ophthalmologicals - ozurdex är indicerat för behandling av vuxna patienter med fläckvisa ödem efter antingen gren retinal-ven ocklusion (brvo) eller central retinal-ven ocklusion (crvo). ozurdex är indicerat för behandling av vuxna patienter med inflammation i bakre segmentet av ögat presentera så andra uveit. ozurdex är indicerat för behandling av vuxna patienter med nedsatt syn på grund av diabetiska makulaödem ödem (dme) som är pseudophakic eller som anses inte tillräckligt lyhörd för, eller är olämpliga för icke-kortikosteroidbehandling.

Unión Europea - sueco - EMA (European Medicines Agency)

biogen netherlands b.v. - natalizumab - multipel skleros - selektiva immunsuppressiva medel - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 och 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Suecia - sueco - Läkemedelsverket (Medical Products Agency)

krka d.d., novo mesto - dexametason - tablett - 4 mg - dexametason 4 mg aktiv substans; laktosmonohydrat hjälpämne

Suecia - sueco - Läkemedelsverket (Medical Products Agency)

2care4 aps - dexametason - tablett - 4 mg - dexametason 4 mg aktiv substans; laktosmonohydrat hjälpämne

Suecia - sueco - Läkemedelsverket (Medical Products Agency)

ebb medical ab - dexametason - tablett - 4 mg - dexametason 4 mg aktiv substans; laktosmonohydrat hjälpämne

Suecia - sueco - Läkemedelsverket (Medical Products Agency)

paranova läkemedel ab - dexametason - tablett - 4 mg - dexametason 4 mg aktiv substans; laktosmonohydrat hjälpämne

Suecia - sueco - Läkemedelsverket (Medical Products Agency)

abacus medicine a/s - dexametason - tablett - 4 mg - laktosmonohydrat hjälpämne; dexametason 4 mg aktiv substans

Unión Europea - sueco - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ozanimod hydroklorid - multiple sclerosis, relapsing-remitting; colitis, ulcerative - immunsuppressiva - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

Suecia - sueco - Läkemedelsverket (Medical Products Agency)

2care4 aps - dexametason - tablett - 4 mg - dexametason 4 mg aktiv substans; laktosmonohydrat hjälpämne